HIV inactivation: Time for a second look

AIDS

Volumn 29, Issue 1, 2015, Pages 129-131

  Rios, Adan ^a,c   Poteet, Ethan C ^b   Siwak, Edward B ^b   Anderson, Dallas W ^a   Yao, Qizhi C ^b  

^a PhotoImmune Biotechnology Inc   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

HIV inactivation; HIV preventive vaccine; Prevention

Indexed keywords

ALPHA INTERFERON; ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; ERDOSTEINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA;

AMPLICON; CD4+ T LYMPHOCYTE; CELL INTERACTION; COCULTURE; DENDRITIC CELL; ENVELOPE GENE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; NONHUMAN; PANDEMIC; PRIMARY CELL CULTURE; PRIORITY JOURNAL; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; WILD TYPE; FORECASTING; HIV INFECTIONS;

AIDS VACCINES; FORECASTING; HIV INFECTIONS; HUMANS; VACCINES, INACTIVATED;

EID: 84928008740     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000522     Document Type: Short Survey

References (27)

1. Barre-Sinoussi F, Cherman JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871
2. Pennington H. Smallpox and bioterrorism. Bull World Health Organ 2003; 81:762-767
3. Secretariat Report. Poliomyelitis: intensification of the global eradication initiative. Sixty-seven World Health Assembly. Provisional agenda item 16.4. Geneva: World Health Organization. 21 March 2014
4. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-479
5. Busch MP, Eble BE, Khayam-Bashi H, Heilbron D, Murphy EL, Kwok S, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 1991; 325:1-5
6. Vyas GN. Human peripheral blood mononuclear cell substrate for propagating wild type HIV-1. Dev Biol (Basel) 2001; 106:345-356discussion 356-7
7. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149
8. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus Type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-413
9. Mayerhans A, Vartanian JP, Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res 1990; 18:1687-1691
10. Shrine D, Rodrigo AG, Nickle DC, Mullins JI. Pervasive genomic recombination of HIV-1 in vivo. Genetics 2004; 167:1573-1583
11. Simmonds P, Balfe P, Ludlam CA, Bishop JO, Leigh Brown AJ. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol 1990; 64:5840-5850
12. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289
13. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV 1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557
14. Parrish NF, Gao F, Li H, Giorgi EE, Hannah JB, Parrish EH, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 2013; 110:6626-6633
15. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640
16. Khan P. Do clades matter for HIV vaccines? New York, NY: International AIDS Vaccine Initiative; 2003. vol. 07, no. 2
17. Schonberger L, Kaplan J, Kim-Farley R, Moore M, Eddins D, Hatch M. Control of paralytic poliomyelitis in the United States. Rev Infect Dis 1984; 6 (Suppl 2):S424-S426
18. Marin-Muller C, Rios A, Anderson D, Siwak E, Yao Q. Complete and repeatable inactivation of HIV-1 viral particles in suspension using a photo-label nonnucleoside reverse transcriptase inhibitor. J Virol Methods 2013; 189:125-128
19. Rios A, Quesada J, Anderson D, Goldstein A, Fossum T, Colby-Germinario S, et al. Complete inactivation of HIV-1 using photo-labeled nonnucleoside reverse transcriptase inhibitors. Virus Res 2011; 155:189-194
20. Vyas GN, Stoddart CA, Killian MS, Brennan TV, Goldberg T, Ziman A, et al. Derivation of noninfectious envelope proteins from virions isolated from plasma negative for HIV antibodies. Biologicals 2012; 40:15-20
21. Sheppard WH. Inactivated-or killed-virus HIV/AIDS vaccines. Curr Drug Targets Infect Disord 2005; 5:131-140
22. Chertova E, Bess JW Jr, Crise BJ, Sowder IlRC, Schaden TM, Hilburn JM, et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002; 76:5315-5325
23. Race E, Frezza P, Stephens DM, Davis D, Polyanskaya N, Cranage M, et al. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine 1995; 13:54-60
24. Poon B, Safrit JT, McClure H, Kitchen C, Hsu JF, Gudeman V, et al. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J Virol 2005; 79:4927-4935
25. Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 2004; 20:772-787
26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220
27. Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013; 8:e53629.